Dr. Kurt Brunden

Posted by on Nov 14, 2011

Research Associate Professor
Scientific Director, Marian S. Ware Alzheimer and Benaroya Parkinson’s Disease Drug Discovery Programs

Dr. Burnden’s proposal is close behind Puglieli’s in terms of proximity to animal model testing, after Brunden does some toxicology. Brudens proposal focuses on a family of aminothienopyridizine (ATPZs) compounds that emerged from 290,000 compound screens for drugs to block tangle formation in AD. He has identified several ATPZs that are worthy of bringing forward in animal studies.